Pratosartan

Drug Profile

Pratosartan

Alternative Names: DA 727; KD 3671; KT 3671

Latest Information Update: 12 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kotobuki Seiyaku
  • Developer Boryung Pharmaceutical; Daiichi Sankyo Company; Kotobuki Pharmaceutical
  • Class Antihypertensives; Imidazoles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hypertension
  • Discontinued Atherosclerosis; Diabetic nephropathies; Glomerulonephritis

Most Recent Events

  • 13 Apr 2012 Pratosartan is still in phase III development in South Korea and phase II in Japan for Hypertension
  • 10 Sep 2010 Clinical development is ongoing in Japan and South Korea
  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top